TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00821288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship Intervention
Description: Survivorship Consultation is a one hour consultation in a survivorship clinic. The consultation will be performed by a nurse practitioner under the supervision of a medical oncologist. The consultation will result in a detailed written document outlining the individuals Survivorship Prescription including treatment summary, surveillance recommendations, risk for late-effects, cancer screening recommendations, genetic risk, and life style recommendations. This written document will be provided to the patient and her treating physician. In addition, referrals will be made to appropriate adjunct services as needed (e.g. psychologist, nutritionist, social worker).
Study: NCT03681808

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test
Description: Soft Contact Lens
Study: NCT02161224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: Oral
Study: NCT00800319

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume matched placebo; oral solution; single dose
Study: NCT02046174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RENCA macrobeads
Study: NCT00928642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate by mouth
Description: imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
Study: NCT02036164

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic radiation
Description: Radiation:~* Pelvic radiation 1.8 Gy/ day, 5 days/ week, 6 weeks~* Brachytherapy 30-35 Gy for 4-5 times

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic radiation
Description: Radiation:~* Pelvic radiation 1.8 Gy/ day, 5 days/ week, 6 weeks~* Brachytherapy 30-35 Gy for 4-5 times

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg m2 i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 i.v.
Study: NCT00716430

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality Improvement Programme
Description: Quality Improvement training programme
Study: NCT01367704

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching Boys Into Men program
Description: Coaching Boys into Men (CBIM) program consists of a 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rationale for CBIM and the CBIM Coaches Kit. The Coaches use this CBIM toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching Boys Into Men program
Description: Coaching Boys into Men (CBIM) program consists of a 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rationale for CBIM and the CBIM Coaches Kit. The Coaches use this CBIM toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.
Study: NCT01244581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Description: Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo mixture in two daily doses for 7 days
Study: NCT03355560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg IV infusion
Study: NCT03606447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: \[14C\]-Uproleselan
Study: NCT01460355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: injection of 5U in 0.1ml of saline solution will be given to the recessed muscle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: injection of 0,1ml of saline solution will be given to the recessed muscle
Study: NCT02793596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obstetrical patients
Description: Epidural waveform analysis as a confirmation of loss of Resistance
Study: NCT04522154

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnet resonance imaging
Description: Patients will receive a cardiac magnet resonance tomography before and 3-month after the procedure
Study: NCT03535662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orvepitant
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orvepitant
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Once daily dosing for 10 days
Study: NCT04060381

Intervention type: DRUG
Intervention: Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine
Description: Treatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit

Intervention type: DRUG
Intervention: Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine
Description: Treatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit
Study: NCT04806490

Intervention type: DIAGNOSTIC_TEST
Intervention: the diagnosis for Yin Deficiency Syndrome
Description: The measurement of the standard scale for syndrome differentiation of Yin Deficiency Syndrome

Intervention type: DIAGNOSTIC_TEST
Intervention: the diagnosis for Yin Deficiency Syndrome
Description: The measurement of the standard scale for syndrome differentiation of Yin Deficiency Syndrome
Study: NCT01396265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: multiple doses
Study: NCT02885870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combination of multiparametric MRI and electrophysiology
Description: MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combination of multiparametric MRI and electrophysiology
Description: MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis
Study: NCT01162174

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oligonol
Study: NCT00821288

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facing Forward
Description: Facing Forward: Life after Cancer Treatment is a guide for people who were treated for cancer published by the NCI. It is a 24-page manual that summarized many key issues of interest to cancer survivors during the re-entry phase, and contains sections on medical care after treatment, symptoms after treatment, feelings after treatment, social relationships after cancer treatment, and dealing with practical matters such as insurance and employment. The manual is available in English and Spanish. This will be given at the time of registration and the table of contents will be reviewed with the patient.
Study: NCT02109913

Intervention type: DRUG
Group type: OTHER
Intervention: Everolimus plus Exemestane
Description: Everolimus 10mg, oral, daily; exemestane 25 mg, oral, daily. Number of Cycles: until progression or unacceptable toxicity develops. From all patients, 4 additional blood samples, 6ml each, will be collected and an optional tumor biopsy will be taken, if eligible.
Study: NCT00928642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Intravenous
Description: Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
Study: NCT00842712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cis will be administered at a dose of 80 mg/m\^2 as intravenous infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cis will be administered at a dose of 80 mg/m\^2 as intravenous infusion on Day 1.
Study: NCT03909724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS 102
Description: After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
Study: NCT01732861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292
Description: CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.
Study: NCT03034278

Intervention type: OTHER
Intervention: Not applicable - no intervention
Description: Not applicable - no intervention, observational survey study.
Study: NCT00842712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (Gem) will be administered at a dose of 1250 mg/m\^2 as intravenous infusion on Days 1 and 8.
Study: NCT03004833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Infusion of Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Infusion of Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Infusion of Adriamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Infusion of Adriamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Infusion of Vinblastine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Infusion of Vinblastine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Infusion of Dacarbazine
Study: NCT03004833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Infusion of Dacarbazine
Study: NCT00842712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine (Vin) will be administered at a dose of 25 mg/m\^2 as intravenous infusion on Days 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine (Vin) will be administered at a dose of 25 mg/m\^2 as intravenous infusion on Days 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Cil will be administered at a dose of 2000 mg as intravenous infusion once weekly over 1 hour on Days 1, 8 and 15 of each 3-week cycle until progressive disease, death, unacceptable toxicity, or consent withdrawal.
Study: NCT03611556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arm description.
Study: NCT00842712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1, 4, 8, 11, 15, and 18 of each 3-week cycle followed by once weekly administration after end of chemotherapy until progressive disease, death, unacceptable toxicity, or consent withdrawal.
Study: NCT03611556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive IV infusion of gemcitabine as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive IV infusion of gemcitabine as stated in arm description.
Study: NCT01162174

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligonol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligonol
Study: NCT01548729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined pancreatic islet and lung transplantation
Description: Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis
Study: NCT02941861

Intervention type: OTHER
Intervention: Recurrence Rate of HCC after surgery
Description: Recurrence Rate of HCC after surgery

Intervention type: OTHER
Intervention: Recurrence Rate of CCA after surgery
Description: Recurrence Rate of CCA after surgery
Study: NCT04034069

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theta burst stimulation (TBS)
Description: Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.
Study: NCT03611556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Participants will receive IV infusion of gemcitabine as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive IV infusion of gemcitabine as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive IV infusion of gemcitabine as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Participants will receive IV infusion of nab-paclitaxel as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Participants will receive IV infusion of nab-paclitaxel as stated in arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Participants will receive IV infusion of nab-paclitaxel as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Participants will receive IV infusion of nab-paclitaxel as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Participants will receive IV infusion of nab-paclitaxel as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive IV infusion of oxaliplatin as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive IV infusion of oxaliplatin as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Participants will receive IV infusion of folinic acid as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Participants will receive IV infusion of folinic acid as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Participants will receive IV infusion of 5-FU as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Participants will receive IV infusion of 5-FU as stated in arm description.
Study: NCT02721407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retroviral vector-transduced autologous T cells to express CD22-specific CARs
Study: NCT00591136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indibulin
Description: Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months
Study: NCT00317395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otamixaban (XRP0673)
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otamixaban (XRP0673)
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otamixaban (XRP0673)
Description: intravenous administration
Study: NCT00031746

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: soy protein isolate
Description: 25 mg daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: casein proteins
Description: 25 mg daily
Study: NCT04346108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (IGIV)
Description: Participants will receive IGIV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)
Description: Participants will receive IGSC, 20% SC infusion.
Study: NCT04034069

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Theta burst stimulation (TBS)
Description: Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation (TBS)
Description: Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Robot-assisted training
Description: Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device. HandyRehab hand robot (Zunosaki Company Ltd., Hong Kong SAR) will be used for upper limb distal joints training. It is an exoskeleton over the hand which provides power-driven extension and grasping force to the fingers and thumb in order to assist the patient to open and close the paretic hand by means of surface electromyography-triggered from the signals through the forearm extensors and flexors.
Study: NCT04346108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)
Description: Participants will receive IGSC, 20% SC infusion.